- Dicerna Pharmaceuticals (DRNA) presents updated data from its ongoing PHYOX 1 Phase 1 trial evaluating DCR-PHXC, a GalXC product candidate.
- The data showed post-dose reductions in 24-hour urinary oxalate levels in adult and adolescent study participants with primary hyperoxaluria type 1 (PH1) and type 2 (PH2).
- A single dose led to normalization or near-normalization of urinary oxalate levels in a majority of participants and was generally well-tolerated.
-
DCR-PHXC is an RNAi therapeutic based on the company's GalXC platform which enables subcutaneous administration.